Structure–Activity Relationship Study of Covalent Pan-phosphatidylinositol 5‑Phosphate 4‑Kinase Inhibitors

Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are important molecular players in a variety of diseases, such as cancer. Currently available PI5P4K inhibitors are reversible small molecules, which may lack selectivity and sufficient cellular on-target activity. In this study, we present a new...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS medicinal chemistry letters 2020-03, Vol.11 (3), p.346-352
Hauptverfasser: Manz, Theresa D, Sivakumaren, Sindhu C, Yasgar, Adam, Hall, Matthew D, Davis, Mindy I, Seo, Hyuk-Soo, Card, Joseph D, Ficarro, Scott B, Shim, Hyeseok, Marto, Jarrod A, Dhe-Paganon, Sirano, Sasaki, Atsuo T, Boxer, Matthew B, Simeonov, Anton, Cantley, Lewis C, Shen, Min, Zhang, Tinghu, Ferguson, Fleur M, Gray, Nathanael S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are important molecular players in a variety of diseases, such as cancer. Currently available PI5P4K inhibitors are reversible small molecules, which may lack selectivity and sufficient cellular on-target activity. In this study, we present a new class of covalent pan-PI5P4K inhibitors with potent biochemical and cellular activity. Our designs are based on THZ-P1-2, a covalent PI5P4K inhibitor previously developed in our lab. Here, we report further structure-guided optimization and structure–activity relationship (SAR) study of this scaffold, resulting in compound 30, which retained biochemical and cellular potency, while demonstrating a significantly improved selectivity profile. Furthermore, we confirm that the inhibitors show efficient binding affinity in the context of HEK 293T cells using isothermal CETSA methods. Taken together, compound 30 represents a highly selective pan-PI5P4K covalent lead molecule.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.9b00402